Street Calls of the Week
PARSIPPANY, N.J. - Zoetis Inc. (NYSE:ZTS), a leading animal health company with a market capitalization of $62.5 billion and impressive gross margins of 71.5%, announced Friday that its canine osteoarthritis pain treatment Lenivia (izenivetmab) received a positive opinion from the European Medicines Agency’s Committee for Veterinary Medicinal Products, recommending marketing authorization in the European Union. According to InvestingPro analysis, the company maintains strong financial health with a "GOOD" overall rating.
The European Commission is expected to make a final decision during the fourth quarter of 2025, with commercial availability anticipated in 2026, according to the company’s press release statement.
Lenivia is designed as an antibody therapy that reduces osteoarthritis pain in dogs for three months with a single injection by targeting nerve growth factor (NGF), a mediator of pain and inflammation. The company reported that dogs in a nine-month field study showed increased mobility and decreased pain after treatment.
Nearly 40 percent of dogs may be affected by osteoarthritis pain, a chronic and progressive joint disease characterized by inflammation and joint breakdown.
If approved, Lenivia would join Librela (bedinvetmab) in Zoetis’ portfolio of osteoarthritis pain products for dogs. While both are monoclonal antibodies targeting NGF, Lenivia binds to a different site on NGF and is designed to provide longer-lasting pain reduction.
"If approved, Lenivia will be our first long-acting therapy that reduces OA pain in dogs, leading to improved quality of life and mobility. It also provides added convenience for pet owners who want to bring their dogs in for an injection just once every three months," said Richard Goldstein, Global Chief Medical Officer at Zoetis.
Zoetis, which generated revenue of $9.3 billion in 2024, focuses on animal health products including medicines, vaccines, diagnostics and technologies. Currently trading near its 52-week low, InvestingPro analysis suggests the stock is moderately undervalued, with 12 consecutive years of dividend increases and a current yield of 1.4%. For detailed insights and more exclusive financial metrics, investors can access the comprehensive Pro Research Report, available to InvestingPro subscribers.
In other recent news, Zoetis Inc. declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025, payable to shareholders on December 2, 2025. The company also received conditional approval from the U.S. Food and Drug Administration for its Dectomax-CA1 Injectable, marking it as the first approved treatment in the U.S. for New World screwworm infestations in cattle. This approval applies to various types of cattle and provides protection against reinfestation for up to 21 days. Additionally, Zoetis announced a positive opinion from the European Medicines Agency’s Committee for Veterinary Medicinal Products for its cat osteoarthritis treatment, Portela. If approved, Portela would be the first long-acting monoclonal antibody therapy for cats, offering pain relief for three months with a single injection. Zoetis has also entered a new $1.25 billion revolving credit facility with a syndicate of banks, replacing its previous agreement. This new facility, led by JPMorgan Chase, allows for an increase in commitments up to $1.75 billion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.